Renalytix Statistics

Total Valuation

Renalytix has a market cap or net worth of GBP 8.52 million. The enterprise value is 8.22 million.

Market Cap	8.52M
Enterprise Value	8.22M

Important Dates

The next estimated earnings date is Wednesday, June 24, 2026.

Earnings Date	Jun 24, 2026
Ex-Dividend Date	n/a

Share Statistics

Renalytix has 437.02 million shares outstanding. The number of shares has increased by 248.09% in one year.

Current Share Class	437.02M
Shares Outstanding	437.02M
Shares Change (YoY)	+248.09%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	5.60%
Owned by Institutions (%)	70.52%
Float	363.45M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	3.48
PB Ratio	-9.56
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-0.56
EV / Sales	3.35
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-0.85

Financial Position

The company has a current ratio of 1.57

Current Ratio	1.57
Quick Ratio	1.39
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	-0.44
Interest Coverage	-20.88

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	n/a
Return on Invested Capital (ROIC)	-1,360.82%
Return on Capital Employed (ROCE)	-371.11%
Weighted Average Cost of Capital (WACC)	13.69%
Revenue Per Employee	53,302
Profits Per Employee	-321,428
Employee Count	46
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	-1.04M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -75.00% in the last 52 weeks. The beta is 1.97, so Renalytix's price volatility has been higher than the market average.

Beta (5Y)	1.97
52-Week Price Change	-75.00%
50-Day Moving Average	3.19
200-Day Moving Average	6.09
Relative Strength Index (RSI)	17.13
Average Volume (20 Days)	1,043,028

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Renalytix had revenue of GBP 2.45 million and -14.79 million in losses. Loss per share was -0.04.

Revenue	2.45M
Gross Profit	1.11M
Operating Income	-12.41M
Pretax Income	-15.83M
Net Income	-14.79M
EBITDA	n/a
EBIT	-12.41M
Loss Per Share	-0.04

Full Income Statement

Balance Sheet

The company has 4.61 million in cash and 4.31 million in debt, with a net cash position of 297,200 or 0.00 per share.

Cash & Cash Equivalents	4.61M
Total Debt	4.31M
Net Cash	297,200
Net Cash Per Share	0.00
Equity (Book Value)	-891,600
Book Value Per Share	-0.00
Working Capital	2.30M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -9.66 million and capital expenditures -74,300, giving a free cash flow of -9.73 million.

Operating Cash Flow	-9.66M
Capital Expenditures	-74,300
Depreciation & Amortization	n/a
Net Borrowing	-3.09M
Free Cash Flow	-9.73M
FCF Per Share	-0.02

Full Cash Flow Statement

Margins

Gross Margin	45.45%
Operating Margin	-506.06%
Pretax Margin	-645.45%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Renalytix does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-248.09%
Shareholder Yield	-248.09%
Earnings Yield	-173.50%
FCF Yield	-114.22%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Renalytix has an Altman Z-Score of -27.32 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-27.32
Piotroski F-Score	3